Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Up to 30% of patients undergoing intracranial surgery present moderate to severe pain. In this type of surgery, the restriction of the pharmacopoeia, which goes against the concept of multimodal analgesia, results in the important use of opioids not without consequences in terms of complications. Numerous studies have highlighted the benefits of scalp blocks in postoperative pain. The originality of this study lies firstly in the fact that the scalp blocks will be guided by ultrasound and secondly, the incidence of severe pain after scalp blocks will be evaluated
In neurosurgery, up to 30% of patients experience severe pain (Numeric Pain Rating Scale > 5) after craniotomy. In order to ensure optimal patient comfort during the perioperative period, multimodal analgesia is the rule. However, the use of certain analgesics in this type of surgery is discussed.
The two analgesics most used in this type of surgery are paracetamol and opioids. The latter, used in large quantities, can lead to an increase in drowsiness, disrupt the postoperative neurological clinical examination (Glasgow score, etc.), cause nausea/vomiting or respiratory depression which will increase complications and the length of stay of patients. Despite the use of morphine and its adverse effects, some study highlighted the high incidence of pain, particularly severe pain in post-craniotomy surgery.
Whether it is to improve postoperative pain or to decrease the intraoperative hemodynamic response, many studies have underlined the interest of scalp block in the postoperative analgesia of craniotomies. Even if large randomized clinical trials are necessary, scalp blocks have been evaluated in subdural hematoma evacuation surgeries, in awake neurosurgeries or in Arnold neuralgia. Intraoperative arterial hypertension induces a risk of increased bleeding and an increase in intracranial pressure with the consequent consequences on cerebral perfusion pressure. These hemodynamic variations, whether intra or post operative, are a source of adverse events.
However, the results of the different studies appear to be discordant and are more interested in the comparison of pain scores and not in the incidence of severe pain. Scalp blocks are mostly performed from anatomical landmarks. In addition, the scalp, which is richly vascularized, is a source of intravascular passage of local anesthetics. Ultrasound-guided scalp blocks are part of this morphine-sparing and multimodal analgesia approach and would allow the realization of a locoregional anesthesia by decreasing, through the use of ultrasound, the risks of intravascular injection and the quantity of local anesthetic.
This study is one of the first to evaluate the impact of an ultrasound-guided scalp block on the incidence of severe postoperative pain (Numeric Pain Rating Scale > 4) in supratentorial intracranial surgery.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Experimental group | Experimental | Patient managed in the neurosurgical unit for supratentorial intracranial surgery randomized in the experimental group |
|
| Control group | Active Comparator | Patient managed in the neurosurgical unit for supratentorial intracranial surgery randomized in the control group |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Echo-guided scalp blocks | Drug | Classic anesthetic strategy in association with echo-guided scalp blocks |
|
| Measure | Description | Time Frame |
|---|---|---|
| Intense post-operative pain | The primary outcome measure will be a composite outcome including:
| up to 6 hours after extubation (day 0) |
| Measure | Description | Time Frame |
|---|---|---|
| Absolute pain | Pain will be assessed using a visual analog scale (from 0: no pain to 10: maximum pain). | at Day 0, hourly until 6 hours after extubation and 24 hours after intervention |
| Morphine consumption. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Grégoire Chadefaux, MD | Contact | +33 05 57 87 02 02 | gregoire.chadefaux@chu-bordeaux.fr | |
| Grégoire CANE, MD | Contact | +33 05 57 87 02 01 | gregoire.cane@chu-bordeaux.fr |
| Name | Affiliation | Role |
|---|---|---|
| Grégoire CANE, MD | University Hospital, Bordeaux | Study Director |
| Grégoire CHADEFAUX, MD | University Hospital, Bordeaux | Principal Investigator |
| Antoine BENARD, MD |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bordeaux university hospital | Bordeaux | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000377 | Agnosia |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
comparative, superiority, single-center, randomized clinical trial with two parallel groups
Not provided
Not provided
Not provided
| Classic anesthetic strategy | Drug | classic anesthetic strategy with postoperative analgesia associating Paracetamol and Morphine with standardized dose. |
|
Recording the amount of morphine consumed
| at Day 0, hourly until 6 hours after extubation and 24 hours after intervention |
| Incidence of Postoperative nausea and vomiting | The occurrence of postoperative nausea and vomiting will be recorded and defined by at least one of the following:
| at day 0 : 6 hours and 24 hours after intervention |
| Chronic post-operative pain | Presence of persistent headache or neuropathic pain at the scar site using a visual analog scale | 3 months after Day 0 |
| Infection | The occurrence of an infection at the surgical site will also be recorded. | 3 months after Day 0 |
| University Hospital, Bordeaux |
| Study Chair |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |